Miran Šebeštjen (Miran Sebestjen)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 26

Top Topics

Peripheral Blood

Ejection Fraction

Cardiovascular Disease

Top Venues

Journal of cardiovascular development and disease

International journal of molecular sciences

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Miran Šebeštjen
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values. International journal of molecular sciences 25 (2) (2024)
Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Miran Šebeštjen
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values. International journal of molecular sciences 25 (2) (2024)
Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Miran Šebeštjen
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values. International journal of molecular sciences 25 (2) (2024)
Tadeja Sotler, Miran Šebeštjen
PCSK9 as an Atherothrombotic Risk Factor. International journal of molecular sciences 24 (3) (2023)
Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes 14 (3) (2023)
Tadeja Sotler, Miran Šebeštjen
PCSK9 as an Atherothrombotic Risk Factor. International journal of molecular sciences 24 (3) (2023)
Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes 14 (3) (2023)
Tadeja Sotler, Miran Šebeštjen
PCSK9 as an Atherothrombotic Risk Factor. International journal of molecular sciences 24 (3) (2023)
Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes 14 (3) (2023)
Tadeja Sotler, Miran Šebeštjen
PCSK9 as an Atherothrombotic Risk Factor. International journal of molecular sciences 24 (3) (2023)
Tadeja Sotler, Miran Šebeštjen
PCSK9 as an Atherothrombotic Risk Factor. International journal of molecular sciences 24 (3) (2023)
Barbara Sernek, Rok Kamnikar, Miran Šebeštjen, Anja Boc, Vinko Boc
Smoking and Diabetes Attenuate Number of CD34 + Haematopoietic Stem Cells in Peripheral Blood of Patients with Advanced Peripheral Artery Disease. International journal of molecular sciences 24 (20) (2023)
Jernej Jeras, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen
Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies. Journal of cardiovascular development and disease 9 (12) (2022)
Sabina Ugovšek, Miran Šebeštjen
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall. Journal of clinical medicine 11 (13) (2022)
Jernej Jeras, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen
Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies. Journal of cardiovascular development and disease 9 (12) (2022)
Max Lenz, Manuel Salzmann, Cosmin I Ciotu, Christoph Kaun, Konstantin A Krychtiuk, Andreja Rehberger Likozar, Miran Šebeštjen, Laura Göderle, Sabine Rauscher, Zoriza Krivaja, Christoph J Binder, Kurt Huber, Christian Hengstenberg, Bruno Karl Podesser, Michael J M Fischer, Johann Wojta, Philipp J Hohensinner, Walter S Speidl
Pharmacologic modulation of intracellular Na + concentration with ranolazine impacts inflammatory response in humans and mice. Proceedings of the National Academy of Sciences of the United States of America 119 (29) (2022)
Jernej Jeras, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen
Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies. Journal of cardiovascular development and disease 9 (12) (2022)
Sabina Ugovšek, Andreja Rehberger Likozar, Sanjo Finderle, Gregor Poglajen, Renata Okrajšek, Bojan Vrtovec, Miran Šebeštjen
TNF-α Predicts Endothelial Function and Number of CD34 + Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure. Journal of cardiovascular development and disease 9 (8) (2022)
Tina Levstek, Nik Podkrajšek, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels. Journal of cardiovascular development and disease 9 (5) (2022)
Jernej Jeras, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen
Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies. Journal of cardiovascular development and disease 9 (12) (2022)
Jernej Jeras, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen
Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies. Journal of cardiovascular development and disease 9 (12) (2022)
Katja Hrovat, Andreja Rehberger Likozar, Janja Zupan, Miran Šebeštjen
Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors. Journal of cardiovascular development and disease 9 (7) (2022)
Sabina Ugovšek, Miran Šebeštjen
Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules 12 (1) (2021)
Andreja Rehberger Likozar, Ales Blinc, Katarina Trebušak Podkrajšek, Miran Šebeštjen
LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels. Journal of cardiovascular development and disease 8 (12) (2021)
Andreja Rehberger Likozar, Mark Zavrtanik, Miran Šebeštjen
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. Annals of medicine 52 (5) (2020)
Gregor Poglajen, Ajda Anžič-Drofenik, Gregor Zemljič, Sabina Frljak, Andraž Cerar, Renata Okrajšek, Miran Šebeštjen, Bojan Vrtovec
Long-Term Effects of Angiotensin Receptor-Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction. Diagnostics (Basel, Switzerland) 10 (8) (2020)